Navigation Links
Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients

es. Taking advantage of the high flexibility of its ImmunodrugTM platform, Cytos Biotechnology has built a pipeline of different ImmunodrugTM candidates in various disease areas, of which 6 are currently in clinical development. The Immunodrug™ candidates are developed both in-house and together with Novartis and Pfizer Animal Health. Founded in 1995 as a spin-off from the Swiss Federal Institute of Technology (ETH) in Zurich, the company is located in Schlieren (Zurich). Currently, the company has 130 employees. Cytos Biotechnology AG has been listed on the SWX Swiss Exchange (SWX:CYTN) since October 2002.

For further information please contact:

Dr. Claudine Blaser
Director Corporate Communications
Phone: +41 44 733 47 20
Fax: +41 44 733 47 18
e-Mail: claudine.blaser@cytos.com
Website: www.cytos.com

This foregoing press release may contain forward-looking statements that include words or phrases such as “aimed at”, “will”, “designed”, “indicate”, “could”, “potential”, “intend” or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any other therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of thes
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:3/27/2015)... 27, 2015 Dynatronics Corporation (NASDAQ: DYNT ) ... appointed to the Company,s Board of Directors effective March 23, ... November 2014 of board member Joseph Barton .  ... our Board of Directors represents an important step forward for ... president of Dynatronics.  "Rich is a proven leader and is ...
(Date:3/27/2015)... 27, 2015 Biopharmaceutical Industry Leads Manufacturing ... comes out on top as the country,s manufacturing leader ... report  from ndp│analytics. According to the  analysis , the ... over the last decade, accounting for 27 percent of ... A Short Video on Medicare Part D ...
(Date:3/27/2015)... , March 27, 2015   Cypher ... today announced new data showing that, compared to ... technology provided highly equivalent interpretations of whether ... and did so in a fraction of the ... way for more comprehensive genetic analysis in non-invasive ...
Breaking Medicine Technology:Dynatronics Announces Appointment of Richard J. Linder to Board of Directors 2Week in Review: The Latest from PhRMA 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3
... international study indicates that anti-inflammatory drugs may become a ... (CHD), the leading global cause of death. In investigating ... disease, the researchers used the Cardiochip, a gene analysis ... in the Center for Applied Genomics at The Children,s ...
... Pharma Group today announced that William (Bill) D. Humphries ... Merz Inc., effective March 15, 2012.  In his new ... Dermatology global business unit and will oversee strategic direction ... LLC, Merz Aesthetics, Inc. and Merz Pharma Canada, Ltd.  ...
Cached Medicine Technology:Gene Chip, Invented by Children's Hospital of Philadelphia Scientist, Pinpoints New Target to Prevent Heart Disease 2Gene Chip, Invented by Children's Hospital of Philadelphia Scientist, Pinpoints New Target to Prevent Heart Disease 3The Merz Pharma Group Appoints William D. Humphries As New North American Chief Executive Officer 2
(Date:3/28/2015)... 2015 Genomic medicine experts have sequenced ... for the first time, key information for understanding and ... the newly posted story on the Surviving Mesothelioma ... British Columbia, the British Columbia Cancer Agency, and PhenoPath ... underlying molecular alterations and mutations that can lead to ...
(Date:3/28/2015)... Portland, OR (PRWEB) March 28, 2015 ... in the media regarding recent changes and proposals around ... TV , current and former collegiate student-athletes across a ... experiences and reflect on common challenges. The special panel ... the country in sports ranging from football, track and ...
(Date:3/28/2015)... Healthpointe’s otolaryngologists, medical practitioners who attend ... disorders, are now offering a wide variety of treatments ... characterized by the presence of phantom sounds or ringing ... is a prevalent symptom that can arise due to ... tinnitus can impede a person’s quality of life. , ...
(Date:3/28/2015)... Viejo, California (PRWEB) March 28, 2015 ... announced a new overlay entitled Scratches 5K from Pixel ... grungy scratch effects to any media inside Final Cut ... Studios. “StoryBoard Corporate saves time and is an effective ... media using FCPX Overlay Scratches 5K's intuitive grunge overlays. ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Purity ... dietary supplements announces the release of their revolutionary ... shown in two randomized, double-blind, placebo-controlled clinical studies ... waist and hip size. MuffinStop™ is a combination ... and Garcinia mangostana, fused together to create one ...
Breaking Medicine News(10 mins):Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2
... remarkable operation, a multi-disciplinary team of surgeons at the Ohio ... Hospital and Richard J. Solove Research Institute (OSUCCC James) ... patient, and used the healthy, living bones from his amputated ... remaining right pelvis to support a high-tech prosthetic leg. ...
... is usually viewed as more cost effective, MRI is ... performing a cost utility analysis, utilizing an ultrasound as ... with pre-operative MRI to identify alternative and concurrent diagnoses, ... to research being presented at the 2011 American Roentgen ...
... Reporter , WEDNESDAY, May 4 (HealthDay News) -- In ... inhaled steroids, British researchers found that the oral medications ... oral medications, known as leukotriene-receptor antagonists, "have shown similar ... considered for any patient, not as a last option ...
... the May issue of the journal Health Affairs , ... impact of toxic chemicals and air pollutants in the environment, ... and also those already on the market. Leonardo ... Mount Sinai School of Medicine, analyzed the costs of conditions ...
... Maureen Salamon HealthDay Reporter , WEDNESDAY, May 4 ... a concussion while playing sports should immediately pull players off ... kid -- to avoid a potentially permanent brain injury, according ... conference on youth sports injury prevention held by Safe Kids ...
... KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) has ... to 18 South African scientists and students to help ... Africa. These are the first Collaborative Grants awarded ... collaboration between the University of KwaZulu-Natal (UKZN) and the ...
Cached Medicine News:Health News:Ohio State surgeons rebuild pelvis of cancer patient 2Health News:Ohio State surgeons rebuild pelvis of cancer patient 3Health News:Ultrasound combined with pre-operative MRI is cost effective in evaluating rotator cuff tears 2Health News:Asthma Pills Work as Well as Inhaled Steroids: Study 2Health News:Asthma Pills Work as Well as Inhaled Steroids: Study 3Health News:Estimated costs of environmental disease in children at $76.6 billion per year 2Health News:Estimated costs of environmental disease in children at $76.6 billion per year 3Health News:Football Legend Steve Young Urges Kids, Parents to Play It Safe 2Health News:Football Legend Steve Young Urges Kids, Parents to Play It Safe 3Health News:K-RITH awards grants to foster teamwork among South African TB/HIV scientists 2
No. 1. 30 mm conventional blades. Thin well-rounded tips....
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Shaft angled 45 degrees. Manufactured in titanium....
Solid 13.5 mm wide by 5 mm deep blades. Edge of blades serrated. Dull finish....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Medicine Products: